LEADER 01919oam  22004934a 450 
001 9910695363803321
005 20060928170616.0
035   $a(CKB)5470000002369111
035   $a(OCoLC)70713396
035   $a(EXLCZ)995470000002369111
100   $a20050803d2005      ua             0
101 0 $aeng
135   $aurcn|---|||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aEnantiomeric analysis of ephedrines and norephedrines$b[electronic resource] $efinal report /$fS.M. Wang ... [and others]
210  1$aWashington, DC :$cU.S. Dept. of Transportation, Federal Aviation Administration, Office of Aerospace Medicine ;$aFt. Belvior, VA :$cAvailable through the Defense Technical Information Center ;$aSpringfield, VA :$cAvailable through the National Technical Information Services Office of Aerospace Medicine,$d[2005]
215   $aiii, 10 pages $cdigital, PDF file
300   $aTitle from PDF t.p. (viewed May 30, 2006).
300   $a"April 2005."
300   $a"DOT/FAA/AM-05/8."
320   $aIncludes bibliographical references (pages 3-4).
517   $aEnantiomeric analysis of ephedrines and norephedrines 
606   $aEphedrine$xAnalysis
606   $aPhenylpropanolamine$xAnalysis
606   $aEphedrine$xanalysis
606   $aNorepinephrine$xanalysis
606   $aDesigner Drugs$xanalysis
608   $aTechnical Report.
615  0$aEphedrine$xAnalysis.
615  0$aPhenylpropanolamine$xAnalysis.
615 12$aEphedrine$xanalysis.
615 12$aNorepinephrine$xanalysis.
615 22$aDesigner Drugs$xanalysis.
701   $aWang$b S. M$01381312
712 02$aUnited States.$bOffice of Aerospace Medicine.
801  0$bNLM
801  1$bNLM
801  2$bGPO
906   $aBOOK
912   $a9910695363803321
996   $aEnantiomeric analysis of ephedrines and norephedrines$93423822
997   $aUNINA